○Anna Rosell (Neurovascular Research Laboratory, Institut de Recerca, Hospital Vall d'Hebron, Barcelona, Spain)
Session information
Symposium
[S-28] Symposium 28 Novel therapeutic strategies against ischemic stroke from the perspective of neuro-glial-vascular unit
Fri. May 21, 2021 8:00 AM - 9:30 AM Room 06 (ICC Kyoto 2F Room B-2)
Chair:Maki Takakuni(Kyoto University Graduate School of Medicine),Kanazawa Masato(Department of Neurology, Brain Research Institute, Niigata University)
Recent progress about stroke research has been revealing that cell-cell interactions among various cell types in the brain contribute to the pathology of cerebral infarction. However, detailed pathomechanisms remain unclear, and there is currently no treatment that can comprehensively improve the "neuro-glial-vascular unit" in cerebral infarction. The purpose of this symposium is to summarize and discuss the findings of each researcher from the perspective of elucidating the dynamics of the "neuro-glial-vascular unit" in cerebral infarction and its therapeutic application. Although thrombectomy and thrombolysis has advanced in the hyperacute phase of ischemic stroke, its indication is limited, and there is an urgent need to develop new therapeutic approaches for the post-acute phase of ischemic stroke. This symposium will provide us with hints on how to develop new therapeutic strategies against ischemic stroke.
○Masato Kanazawa (Department of Neurology, Brain Research Institute, Niigata University, Japan)
○Nobukazu Miyamoto1, Shunsuke Magami2, Kennichiro Hira1, Toshiki Inaba1, Yuji Ueno1, Nobutaka Hattori1 (1.Department of Neurology, Juntendo University school of medicine, Japan, 2.Department of Neurosurgery, Juntendo University school of medicine)
○Mikiya Beppu1, Takayuki Nakagomi2,3, Toshinori Takagi1, Akiko Doi2,3, Tomohiro Matsuyama2, Shinichi Yoshimura1 (1.Hyogo College of Medicine, Department of Neurosurgery, Japan, 2.Hyogo College of Medicine, Institute for Advanced Medical Sciences, 3.Hyogo College of Medicine, Department of Therapeutic Progress in Brain Diseases)
○Takakuni Maki (Kyoto University Graduate School of Medicine, Japan)